Visual field defects and vigabatrin: An update;Gesichtsfelddefekte unter vigabatrin: Update

Aktuelle Neurologie

Volumn 29, Issue SUPPL. 1, 2002, Pages

  Schmitz, Bettina ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG WITHDRAWAL; EPILEPSY; HIGH RISK PATIENT; HUMAN; PATHOGENESIS; PREVALENCE; RETINA DISEASE; RISK FACTOR; VISUAL FIELD DEFECT; WEST SYNDROME;

EID: 0036091048     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-27806     Document Type: Conference Paper

References (17)

1. Severe persistent visual field constriction associated with vigabatrin
2. Arzneimittelkommission der deutschen ärzteschaft. Persistierende gesichtsfeldeinschränkungen unter vigabatrin
3. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
4. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study
5. Visual field constriction is not limited to children treated with vigabatrin
6. Visual impairment in children with epilepsy treated with vigabatrin
7. Vigabatrin-associated visual field defects in children
8. Antiepileptikainduzierte sehstörungen
9. Absence of concentric visual field defects in patients with initial tiagabine monotherapy
10. Visual field defects under treatment with Vigabatrin, Carbamazepine and Valproate: A prospective study
11. Visual field constriction in children with epilepsy on vigabatrin treatment
12. Recovery of visual field constriction following discontinuation of vigabatrin
13. Reversibility of vigabratin-induced visual-field defect
14. Vigabatrin: Reversibility of severe concentric visual field defects after early detection and drug withdrawal: A case report
15. Sind vigabatrin-assoziierte gesichtsfeldeinschränkungen asymptomatisch?
16. Der derzeitige stellenwert von vigabatrtin (Sabril) in der epilepsiebehandlung - Ergebnisse einer konsensuskonferenz